Skip to content
주식
2009.09.08 08:03

Access Pharmaceuticals

조회 수 10247 추천 수 0 댓글 0
?

단축키

Prev이전 문서

Next다음 문서

크게 작게 위로 아래로 댓글로 가기 인쇄
?

단축키

Prev이전 문서

Next다음 문서

크게 작게 위로 아래로 댓글로 가기 인쇄

Access Pharmaceuticals

Access Pharmaceuticals Inc. (ACCP.OB) stocks Price
2009년1월주가:0.8$
2009년9월4일주가:3.60$
상승율:350%(8월기준 최고상승율480%)
 
 
세계시장규모.
MuGard:50억달러
ProLindac:20억달러
 
아시아시장 라이센스는:JCOM(Korea).
MuGard:2009년 판매개시.
ProLindac:2009년3상진행완료(중국, 한국). 2010년 판매개시.
2009년2월6일:미 아세스사와 뮤가드및 프로린닥 생산 및 판매 라이센스 계약
2009년4월2일:관계사 보락과 주식교환(보락지분율6.8%)
2009년9월현재:보락 뮤가드생산공장 진척율 90%10월초순 완공예정.프로린닥생산시설 진척율60%.연말완공
9월9일 미국 아세스사에서 중대발표예정
 
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 
 
Access to Provide Update on MuGard Global Commercial Launch and ProLindac Clinical Development Plans
 
DALLAS, Sept. 1 /PRNewswire-FirstCall/ ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board : ACCP) announced today that Access will present at the Rodman & Renshaw 11th Annual Healthcare Conference to be held September 9-11, 2009 at the New York Palace Hotel in New York City. Jeffrey B. Davis, President and CEO of Access is scheduled to speak on Friday, September 11, 2009 at 10:50 am EDT in the Fahnestock Salon (5th Floor) and will give a corporate overview and discuss the Company"s product opportunities.
The presentation will be available via a webcast and can be accessed at: http://www.wsw.com/webcast/rrshq15/accp.ob .The replay can be obtained at the same link for up to 90 days after the live presentation.
 
About MuGard: MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, used prophylactically for patients undergoing chemotherapy and radiation therapy, is estimated to be in excess of $5 billion world-wide.
About ProLindac(TM): ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac"s unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access has previously announced that it has licensed ProLindac to Aosaikang Medicinal Group ("ASK") for the Greater China Region and to JCOM, Ltd for South Korea. Under these agreements both of these partners will be conducting Phase 2 combination studies with ProLindac in specific tumor types at their expense based on these results.

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access" products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website atwww.accesspharma.com.

로그인 후 댓글쓰기가 가능합니다.

?

List of Articles
번호 분류 제목 날짜 조회 수
200 주식 주식투자, 출산 장려 관련주에 대한 관심을 가질때 2009.08.09 17842
199 주식 제이콤이 에스티큐브의 똥꾸녕만 쫒아다니는 이유 2009.08.12 15418
198 주식 KCI 기업분석 및 매매전략 2009.07.01 14548
197 주식 버블과 붕괴 1 2010.12.22 13328
196 주식 MCTT(엠씨티티)와 코어포올 합병을 이의제기하는 에스티씨라이프 2 2 2009.08.28 12320
195 주식 게임처럼 주식투자하기 - SK브로드밴드 1 file 2009.08.03 12164
194 주식 게임처럼 주식투자하기 - 솔고바이오 2009.07.30 11759
193 주식 게임처럼 주식투자하기 - 젠트로 2009.07.30 11389
192 주식 주식시장의 바닥과 꼭지의 뚜렷한 조짐현상 2009.09.10 11253
191 주식 주식투자 수익내기 이런방법도 있다. 1 2009.08.19 10902
190 주식 X-ing API 1 3 2010.10.28 10708
189 주식 게임처럼 주식투자하기 - SNH 1 file 2009.07.02 10419
188 주식 수렴끝 확산시작 차트흐름 읽기 2 2009.07.06 10356
187 주식 다차원적인 나의 주식투자 철학 2009.09.22 10309
186 주식 황우석 사태에 대한 아이러브 황우석 입장 2009.08.26 10258
» 주식 Access Pharmaceuticals 2009.09.08 10247
184 주식 이건희 회장의 경영복귀와 스마트폰 2010.03.25 10081
183 주식 게임처럼 주식투자하기 - 이지바이오, 젠트로 file 2009.07.28 9804
182 주식 주식투자에서 원칙이 어렵다? 2014.10.24 9773
181 주식 유상증자액이 시가총액보다 높은 쎄라텍 분석 2009.08.25 9719
Board Pagination Prev 1 2 3 4 5 ... 10 Next
/ 10

http://urin79.com

우린친구블로그

sketchbook5, 스케치북5

sketchbook5, 스케치북5

나눔글꼴 설치 안내


이 PC에는 나눔글꼴이 설치되어 있지 않습니다.

이 사이트를 나눔글꼴로 보기 위해서는
나눔글꼴을 설치해야 합니다.

설치 취소